Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
George Washington University
Study ID
NCT02964585
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Canagliflozin — DRUG
    100 mg
  • Placebo — DRUG
    1 tablet daily for 16 weeks

Study Details

The investigators hypothesize that Cana may be able to improve number and function of CD34+ endothelial progenitor cells. The investigators also propose that this expected cardiovascular benefit is independent of HbA1C reduction. Subjects will begin taking 100 mg of Cana or placebo after initial 4 weeks. Subjects will be withdrawn from the study if the medication or placebo is not tolerated.

Key Dates

Start date
Nov 30, 2016
Status verified
Nov 2022
Primary completion
Jan 31, 2020
Completion
Sep 30, 2020

Study Design

Enrollment
34 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Active Arm
    100 mg of Canagliflozin for 16 weeks
  • Placebo Comparator: Placebo Arm
    Placebo for 16 weeks

Primary Outcome Measure

Gene Expression and Function Change of CD34+ Endothelial Progenitor Cells (Protein Expression) [ Time Frame: 16 weeks post Canagliflozin treatment reported ]

Locations (1)

FacilityCityStateZIPSite coordinators
The George Washington University Medical Faculty AssociatesWashington D.C.District of Columbia20037-

Find similar trials in Washington D.C., DC

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
The George Washington University Medical Faculty Associates· Washington D.C., DC

Related Studies